GLOBAL CALL FOR ACTION FOR AIDS VACCINES
coordinated by IAVI.org

This Global Call for Action for AIDS Vaccines will be presented at the United Nations General Assembly Special Session on HIV/AIDS 25-27 June 2001 in New York. The International AIDS Vaccine Initiative (IAVI) is coordinating this effort.

AIDS is the Great Plague of our modern era. Already the epidemic has claimed the lives of more than 20 million men, women and children worldwide. Fully 95% of new HIV infections are in developing countries, where AIDS is undermining economic stability, reversing decades of progress and devastating families and communities.

Amid global tragedy, a preventive vaccine for AIDS offers the best hope of ending the pandemic. The world has eradicated smallpox and has almost eliminated polio with vaccines. Human trials of promising AIDS vaccine candidates are underway; however, no AIDS vaccine is yet available. With 15,000 new HIV infections daily, there is no time to delay.

We, the undersigned, urge all of the world's leaders to take concrete action now to ensure the development of safe, effective and accessible preventive AIDS vaccines for use wherever they are needed.
  • We call for significant new resources to be devoted worldwide to AIDS vaccine research and development. In particular, new resources are needed for development of vaccines that will be applicable for developing countries. These funds must not be diverted from therapeutics or other prevention efforts.

  • We call for governments to commit the necessary resources to provide AIDS vaccines, when they are available, to all who need them without delay. This includes securing binding commitments for financing the purchase and delivery of vaccines for poor countries. Such a clear, unambiguous commitment must be made at the United Nations General Assembly Special Session on HIV/AIDS and other international meetings.

  • We call for further involvement of industry in AIDS vaccine development, as most vaccine-making expertise and capacity reside there. The world's leaders must find innovative ways to assure global access to AIDS vaccines while allowing a reasonable return for industry's investments.

  • We call for support of human trials of vaccines, and we salute trial volunteers, the unsung heroes of vaccine development. Human testing is critical to determining whether a vaccine is effective. Therefore, the world must prioritize efficacy trials of the most promising vaccines. Many selfless men and women have already volunteered, and many more must follow their brave leadership.

  • We call for vaccine research and development to be part of a comprehensive strategy to fight the epidemic. The world must redouble its commitment to existing prevention programs, including education. And all who are sick with AIDS deserve the best treatment possible, regardless of where they live or ability to pay.

  • We call on the public sector of all nations to work with private industry, international agencies and nongovernmental organizations to end the epidemic. No single country, company, organization, community or individual has the resources to go it alone. But each has a unique and essential contribution to make.

Twenty years into the epidemic, AIDS remains a global emergency that demands an effective response. A preventive vaccine is the best hope to end AIDS for all time.
Friday May 18, 2001
Global Call for Action for AIDS Vaccines to Be Presented at Upcoming UN AIDS Meeting
Internet users worldwide can sign at http://www.iavi.org/callforaction to tell world leaders to take decisive, coordinated action to accelerate the development of AIDS vaccines and assure they will be available worldwide.

The petition will be presented at the upcoming United Nations General Assembly Special Session (UNGASS) on HIV/AIDS, to be held 25-27 June in New York. The International AIDS Vaccine Initiative (IAVI) is coordinating this effort.
Date: Tue, 1 May 2001 21:10:31 -0500 (CDT)
Subject: Call to say NO NAMES REPORTING
From: Julie Davids email: jdavids@CritPath.Org
ACT UP
Philadelphia
PO BOX 22439
Philadelphia PA 19110-2439
Phone : 2 1 5 . 7 3 1 . 1 8 4 4
F a x : 2 1 5 . 7 3 1 . 1 8 4 5
E mail : josemarcos35@yahoo.com

May 1, 2001
Immediate action: phone zap
Joel Hirsh, Director of Epidemiology: 717 783 4677
Robert Zimmerman, Secretary of Health 717 705 6436

Call and say: We oppose names-based HIV reporting. We say, no names use unique identifiers instead!

WHY:
HIV names reporting has been proposed by the PA Department of Health in the proposed rulemaking, published April 20, 2001. WE HAVE LESS THAN 30 DAYS TO COMMENT ON THIS PROPOSAL

The long delay of this proposal -- after about two years of public comment -- was a state strategy so that people would lose interest and not care.

This proposal is blatantly racist: information from anonymous HIV test sites show that Blacks, Latinos, prisoners, the poor, and IV drug users are the majority of new HIV cases. Now the federal, state, and Philadelphia governments want their names.

People that may have been exposed to the HIV will not get tested if the state health department will record their names. The state would have you believe that their main concern is the health of people with HIV. That is a lie.

The Medicaid system maintained by the state has been proven to be inadequate and dangerous for people with HIV; they don't need names to fix it, they just have to care enough to fund it.

Talking points:
  • HIV will spread because people will avoid testing if the state records their names.
  • Names reporting will cost taxpayers more than unique identifiers because people will only find out their HIV status after becoming ill, due to their distrust of the state.
  • Unique identifier tracking systems -- based on unbreakable codes, not names -- have been shown to generate equally accurate amount of data on risk data than names reporting.
  • Nearly every AIDS organization in the state has opposed names reporting
  • 95% of people who got tested at Philadelphia's largest anonymous test site said they would not have gotten tested if they thought their name would be reported.

"Patents are there to reward the inventor ... not give them a monopoly."
Luciano Calenti, ACIC Pharmaceuticals, NYTimes 4/24/01
From: Doctors Without Borders doctors1@NewYork.msf.org
Subject: Press Release: International Petition Campaign Launched
Date: 13 Mar 2001 11:04:22 -0500

ONLINE SIGNERS SUPPORT SOUTH AFRICA'S STRUGGLE FOR AIDS MEDICINES
Demand Pharmaceutical Companies Drop Court Case

go directly to petition

New York, March 12, 2001 - Doctors Without Borders/Medecins Sans Frontieres (MSF) has announced the launch of "Drop the Case!" - an international petition drive calling on the 39 pharmaceutical companies suing the South African government to abandon the court case that is stopping South Africans from receiving AIDS drugs.

In 1997, Nelson Mandela signed a law aimed at improving access to medicine, but the pharmaceutical industry immediately filed suit to block it. In the three years in which the companies have tied up this legislation in the courts, more than 400,000 South Africans have died of HIV/AIDS, nearly all without any access to affordable treatments.

"This case has struck a chord with people around the world because it exposes the lengths that the industry will go to protect its patents and profits, despite the immense human cost. There have been demonstrations from Pretoria to New York, from Copenhagen to Manila, demanding access to lifesaving medicines for South Africa. By signing this petition by April 15, individuals around the world can add their voices to the growing chorus of outrage," said Ellen 't Hoen, policy advisor for Doctors Without Borders' Access to Essential Medicines Campaign.

There is mounting international pressure on the 39 companies to drop the case, including statements from many high-level politicians expressing their support for South Africa.

"Every day people with HIV/AIDS who cannot afford essential medicines visit our clinics. I think that it is appalling that the pharmaceutical industry insists on placing profits before people, and continues to oppose the South African government's attempts to improve access to medicines," said Eric Goemaere, MD, coordinator of Doctors Without Borders' AIDS project in South Africa. "I know that thousands - if not millions - of people worldwide agree. I urge them to sign this petition by April 15."

On Monday, March 5, the case opened in the Pretoria High Court. However, despite the mounting death toll, the pharmaceutical industry sought to postpone the case for an additional four months. Instead, the judge granted them three weeks to present data justifying their high prices, and the case will resume on April 18. The petition calls on the 39 companies to drop the case, and calls on governments of industrialized countries to support South Africa's attempts to improve access to medicine. On February 26, Doctors Without Borders sent letters to all pharmaceutical companies involved in the case, including Merck & Co., Inc., Bristol-Myers Squibb Company, and Pharmacia Corporation, demanding that they drop the lawsuit immediately. On March 5, Doctors Without Borders sent a letter to President George W. Bush urging his administration to issue a public statement in support of South Africa's efforts to improve access to medicines for its citizens.

The petition is available on the newly redesigned website of Doctors Without Borders' U.S. office: www.doctorswithoutborders.org and on the international site of Doctors Without Borders www.msf.org

For more information on Doctors Without Borders' Access to Essential Medicines Campaign, see www.accessmed.msf.org
"The necessity is not to have lawyers debating statutory language... The necessity here is getting drugs."
Frederick M. Abbott, government consultant, NYTimes 3/8/01

"Oxfam Joins Campaign to Cut Drug Prices for Poor Nations" New York Times (www.nytimes.com) (02/13/01) P. A5; McNeil Jr., Donald G.
Oxfam, a British charity, has begun a campaign to force drug companies to reduce the prices of lifesaving drugs to poor nations, by joining forces with Doctors Without Borders, ACT-UP, and others who have been of similar mindset. The group plans to concentrate primarily on the world's largest pharmaceutical company, GlaxoSmithKline. Oxfam and advocates plans to attack the drug company through addressing audiences of its major financial backers on Wall Street and in London. "Our message to the big financial house will be that unless the big drug companies do something dramatic soon, they run a serious reputation risk," said Sophia Tickell, head of the campaign. Oxfam is also calling for a $5 billion fund to subsidize drug research for diseases like malaria, elephantiasis, tuberculosis, and sleeping sickness, all of which exist in epidemic proportions in poorer nations. The charity has requested that drug firms contribute part of their royalties from drug sales surpassing $1 billion to the effort. In response to Oxfam's announcement, Glaxo Chairman Sir Richard Sykes called it "political rhetoric to point the finger somewhere else from where it should be."
Community sign-on letter to Glaxo re Ghana/South Africa lawsuits

FOR IMMEDIATE RELEASE CONTACT: Mark Harrington
3 February 2001 212.353.8430 (until 2.3.01)
312.464.1000 (from 2.4.01)
markharrington@aol.com

Global Coalition of AIDS Activists Calls on GlaxoSmithKline to Abandon Lawsuits Blocking Access to Generic Anti-AIDS Drugs in Ghana, South Africa & Uganda

An international coalition of 65 activist groups and over 100 AIDS activists, educators, health care workers and service providers from six continents and many countries around the world today called on GlaxoSmithKline, one of the world's largest drug companies, to withdraw threatened lawsuits in Ghana, Uganda, and South Africa which are intended to block people with AIDS (PWAs) in those countries from having access to generic anti-AIDS medications.

The coalition, led by the Health GAP Coalition, Treatment Action Group (TAG), and Gay Men's Health Crisis (GMHC), took this action because in November 2000, Glaxo threatened to sue Cipla Ltd. of India, a generic pharmaceutical manufacturer, if Cipla continued to sell its generic Duovir, a combination of the AIDS drugs AZT and 3TC (marketed by Glaxo as Combivir).

In addition, Glaxo has joined forty other drug companies in suing the South African government for a 1997 law intended to broaden access to cheap generic drugs in South Africa.

The activists wrote, "We believe that threatening lawsuits to prevent people in poor countries—already staggering under the weight of the AIDS pandemic, excessive debt to western banks, poverty, and underdevelopment—from accessing life-saving antiretroviral medications is simply unacceptable from a moral and humanitarian point of view."

Instead, the activists suggested that Glaxo: Immediately reduce antiretroviral drug prices to levels affordable in poor countries;

  • Match the best generic offering price (Cipla's Duovir sold for $1.72 retail in Ghana);
  • Provide free antiretrovirals in drug donation programs; and/or
  • Allow poor countries to permit generic manufacturers to make or import the drugs.

TAG Senior Policy Director Mark Harrington said, "We are announcing today a Global Day of Solidarity on March 5, the day when the Pharmaceutical Manufacturers Association of South Africa's lawsuit against legal generic drug access comes before the court in South Africa. On that day, some groups will take direct action against drug companies, pharmaceutical trade organizations, or the U.S. Trade Representative, which has just brought action against Brazil for manufacturing generic antiretrovirals. The program in Brazil is reaching over 85,000 people with AIDS and has saved thousands of lives. No other program - whether the UNAIDS Accelerating Access initiative or the much-touted, but so far insignificant, discounts announced by five big drug companies last May - are reaching significant numbers of people with HIV in the world's poorest countries."

The March 5 Global Day of Solidarity was initiated by South Africa's Treatment Action Campaign (TAC), a grassroots advocacy organization which has been struggling to make anti-AIDS drugs available to South Africa's estimated 4.2 million people living with HIV.

Founded in 1992, the Treatment Action Group, is the first and only AIDS organization dedicated solely to advocating for larger and more efficient research efforts, both public and private, towards finding a cure for AIDS. The Treatment Action Group (TAG) fights to find a cure for AIDS and to ensure that all people living with HIV receive the necessary treatment, care, and information they need to save their lives. TAG focuses on the AIDS research effort, both public and private, the drug development process, and our nation's health care delivery systems. We meet with researchers, pharmaceutical companies, and government officials, and resort when necessary to acts of civil disobedience, or to acts of Congress. We strive to develop the scientific and political expertise needed to transform policy. TAG is committed to working for and with all communities affected by HIV.

For further information: www.treatmentactiongroup.org
Name :
Organization :
Email :


5 February 2001
Sir Richard Sykes
Chairman & Chief Executive
GlaxoSmithKline
    Glaxo Wellcome House
    Berkeley Avenue
    Greenford, Middlesex
    UB60NN United Kingdom

M. Jean-Pierre Garnier
Chief Executive Officer
GlaxoSmithKline
    Glaxo Wellcome House
    Berkeley Avenue
    Greenford, Middlesex
    UB60NN United Kingdom		 Mr. David Stout
Chief Operating Officer
Pharmaceutical Operations
    GlaxoSmithKline
    5 Moore Drive
    PO Box 13398
    Research Triangle Park, NC 27709

Mr. John P. Kearney
Chief Executive Officer
GlaxoSmithKline South Africa (Pty) Limited
    44 Old Pretoria Rd.
    PO Box 3388
    Halfway House 1685
    Midrand, Gauteng, South Africa
Dear Sirs:

We are writing as a coalition of AIDS treatment advocates, educators, and service providers to request that GlaxoSmithKline immediately withdraw from participation in threatened legal action regarding the importation of generic antiretroviral medications in Ghana and South Africa.

Specifically we refer to your threats of legal action against Cipla for selling Duovir, its generic form of Combivir, in Ghana (Wall Street Journal, 1 December 2000), and in Uganda (Glaxo-Wellcome letter to Cipla, 20 November 2000), and the announcement by the Pharmaceutical Manufacturers Association of South Africa of its intent to bring suit against the South African government on March 5 (Reuters, 15 January 2001).

As you are not doubt well aware, two-thirds of the world's 34 million HIV infected people live in Africa, the world's poorest continent. UNAIDS estimates that 4.2 million (20%) of South Africa's population of 39.7 million, 820,000 (8.3%) of Uganda's 21 million people, and 340,000 (3.6%) of Ghana's 19 million people are infected with HIV. The per capita income in South Africa is $3,160 per year (although most of the HIV infected population earns far less than that, if they are lucky enough to be employed at all), while the per capita income in Ghana is just $390 per year, and that in Uganda is $320.

We believe that threatening lawsuits to prevent people in poor countries—already staggering under the weight of the AIDS pandemic, excessive debt to western banks, poverty, and underdevelopment—from accessing life-saving antiretroviral medications is simply unacceptable from a moral and humanitarian point of view.

GlaxoSmithKline has several other options before it which would enable it to help increase, rather than decrease, access to antiretroviral medications among infected people in developing countries:
  • Immediately implement, without regard to negotiations with host countries, steep discounts in the prices of antiretroviral drugs to affordable levels.
  • Match the generic offering price (for example, with Cipla, the retail price—not their best price—appears to be $1.72/day for Duovir - just twenty-eight cents lower than Glaxo's own announced discount to $2.00/day for Combivir in Rwanda, Senegal, and Uganda).
  • Provide antiretroviral drugs in donation programs, which may presumably confer some tax benefits for your company.
  • If you choose not to undertake the expense of providing discount antiretroviral drugs to poor countries where they are most desperately needed, permit generic manufacturers to manufacture and distribute them in your stead.
None of these steps would affect your markets in rich countries, which are where your profits come from. According to your own spokesman, quoted in the Wall Street Journal, Africa represents less than one percent of GlaxoSmithKline's revenues or profits. We doubt that you are earning significant profits in Ghana, in Uganda or in South Africa on overpriced medications which few can afford.

We appreciate Glaxo's efforts to develop new treatments for HIV, and we recognize that you have invested significant resources in the development, testing, approval, distribution, and marketing of antiretroviral medications. However, what use are these discoveries for the 95% of the world's HIV infected population which cannot afford them at current prices? Can you really maintain that 30 million people must die because they cannot afford your drugs? We recognize that it is not up to industry alone to resolve the issues of health care infrastructure, political leadership, and social mobilization which responding to the AIDS pandemic necessitates.

However, it is also important for drug companies not to stand in the way of saving the lives of people for whom the price of drugs is often the main, and sometimes the only, obstacle to treatment.

Since Glaxo, along with four other global pharmaceutical companies, announced in May 2000 their intent to provide steep discounts on anti-HIV medications to developing countries, many press releases have been issued, but how many discounted pills have reached anyone in Africa or elsewhere in the developing world? How many lives have been saved?

Over two million people around the world have died of AIDS since that announcement, and now you, along with 39 other companies, are going to court in order to stop the South African government, with the world's worst epidemic, from obtaining life-saving therapies by means established as legal under the TRIPs clause of the World Trade Organisation treaty. The TRIPs clause allows the granting of a compulsory license in cases where there is a national emergency. How could you deny that AIDS constitutes a national emergency in countries such as Ghana and South Africa?

We appeal to you to immediately cease and desist from using the court systems in Ghana, Uganda, South Africa, and elsewhere in the developing world to prevent HIV infected people from accessing life saving antiretroviral medications.

Yours truly,
Mark Harrington, Senior Policy Director, Treatment Action Group (TAG), New York, NY
Julie Davids, Critical Path AIDS Project/Health GAP Coalition, Philadelphia, PA
Gregg Gonsalves, Treatment Advocacy Director, Gay Men's Health Crisis, New York, NY
Asia Russell, ACT UP/Philadelphia, Philadelphia, PA

Actions Traitements, Paris, France
ACT UP/East Bay, Oakland, CA
ACT UP/Philadelphia, Philadelphia, PA
African AIDS Network
African American AIDS Policy & Training Institute, Los Angeles, CA
AIDES Fédération, Paris, France
AIDS Action Baltimore, Baltimore, MD
AIDS Committee of Toronto, Toronto, Canada
The AIDS Consortium, Johannesburg, South Africa
AIDS Foundation of South Africa
AIDSMeds.com, New York, NY
AIDS Research Alliance, West Hollywood, CA
AIDS Treatment Data Network, New York, NY
AIDS Treatment News, Philadelphia, PA
AIDS Vaccine Advocacy Coalition (AVAC), Washington, D.C.
Ama la Vida A.C., Juchitén, Oaxaca, México
American Foundation for AIDS Research (amfAR), New York, NY
Asociación Costarricense de Personas que viven con VIH/SIDA, San José, Costa Rica
Asociación T-4 Batzordea, Bilbao, Spain
Asociación de Usuarios en Mantenimiento con Metadona Organizados, Barcelona, España
Associació Ciutadana AntiSida de Catalunya, Barcelona, Spain
Association for the Treatment of AIDS in Guatemala
Australian Bisexual Network
Australian Federation of AIDS Organizations (AFAO), Sydney, Australia
BASIDA, Aranjuez, Madrid, España
British Columbia Persons with AIDS Society, Vancouver, British Columbia
Canadian Treatment Advocates Council
La Coalition des organismes communautaires de lutte contre le sida, Montréal, Quebec, Canada
Comité Ciudadano anti-Sida de Granada (CONASIGRA), Granada, Spain
Comité Ciudadano anti-Sida de Valencia, Valencia, Spain
Confederación Española de Asociaciones de Padres de Alumnos (CEAPA), Madrid, España
Consumer Project on Technology, Washington, D.C.
Critical Path AIDS Project, Philadelphia, PA
D.C. Care Consortium, Washington, D.C.
Deutsche AIDS-Hilfe e.V., Berlin, Germany
European AIDS Treatment Group (EATG), Düsseldorf, Germany
Foundation for AIDS & Immune Research (FAIR), Los Angeles, CA
Fundación Ecuatoriana EQUIDAD, Quito, Ecuador
Fundación Isamar, Cumanèdo, Sucre, Venezuela
Fundación José de Arimatea, Guayaquil, Ecuador
Fundación para Estudio e Investigación de la Mujer (FEIM), Buenos Aires, Argentina
Fundación Vivir Mejor, Cali, Colombia
Fundación Vivir, Quito, Ecuador
Gay Men's Health Crisis (GMHC), New York, NY
German Treatment Activists Network, Berlin, Germany
Global Campaign for Microbicides
Grupo de Trabajo sobre Tradatimento de VIH (GTT), Barcelona, Spain
Grupo Pela VIDDA/Rio de Janeiro, Brazil
Health GAP Coalition
Hepatitis C Action & Advocacy Coalition (HAAC), New York, NY
Infectious Diseases Journal of Pakistan
Information Center WOMYN FOR WOMYN
Inland Northwest AIDS Coalition, Spokane, WA
International Council of AIDS Service Organizations (ICASO)
International Lesbian & Gay Association (ILGA), Brussels, Belgium
Italian Community Advisory Board, Rome, Italy
Latino Commission on AIDS, Treatment Education Department, New York, NY
LILA (Italian League for the Fight Against AIDS), Italy
Lookout Emergency Aid Society, Vancouver, British Columbia
Middle East Childrens Alliance, Berkeley, CA
Mobilization Against AIDS International, San Francisco, CA
National Association of People with AIDS (NAPWA), USA
National Minority AIDS Council (NMAC), USA
NYU Adult & Pediatric AIDS Clinical Trials Unit Community Advisory Board, New York, NY
Northwest International Health Action Coalition (NIHAC), Seattle, WA
Pro Salud Sexual y Reproductiva, A.C., Cd. De Monterrey, Neuvo León, México
Project Inform, San Francisco, CA
Projecte dels NOMS-SIDA, Catalonia, Spain
Provincetown Positive People with AIDS Coalition (PPPWAC), Provincetown, MA
Red Latinamericana de PVVIH/SIDA para Costa Rica, San José, Costa Rica
Red Mexicana de Personas que Viven con VIH/SIDA, México City, México
Sao Paulo State AIDS/NGO Forum, Sao Paulo State, Brazil
SIDA-STUDI, Barcelona, Spain
Southern Africa Network of AIDS Service Organizations (SANASO), Harare, Zimbabwe
Stop Sida, Barcelona, Spain
Title II Community AIDS National Network
Treatment Action Campaign, South Africa
Treatment Action Group, New York, NY
TRT-5, Paris, France
VIVO POSITIVO, Santiago, Chile
Union Positiva, Miami, FL

Moisés Agosto, New York, NY
Pablo Anamaria, Program of Support of Self Help for HIV People, Lima, Peru
Terje Anderson, Executive Director, National Association of People with AIDS, Washington DC
Naila Baig Ansari, Publisher, Infectious Diseases Journal of Pakistan
Bill Arnold, Title II Community AIDS National Network
Elvia Lucia Avila Azua, Ama la Vida A.C., Juchit=E1n, Oaxaca, México
Mark W. Baker, New England ProACT; CPCRA Community Constituency Group
Joel Beard, aidsinfonyc.org, New York, NY
Getz Bahr, Berliner AIDS-Hilfe e.V., Berlin, Germany
Irl Barefield, Executive Director, AIDS Research Alliance, West Hollywood, CA
Jordi Baroja, SIDA-STUDI, Barcelona, Spain
Thomas G. Blewitt, DAAIR, New York, NY
Carla Bosacoma, SIDA-STUDI, Barcelona, Spain
Ann Brameier, L.Ac., New York, NY
Shari Brenner, HIV Prevention & Services, Cambridge Health Alliance, Cambridge MA
Richard Burzynski, ICASO, Toronto, Canada
Iolanda Cacho, SIDA-STUDI, Barcelona, Spain
José Carbonell, Asociación de Usuarios en Mantenimiento con Metadona Organizados Barcelona, España
George Carter, Direct Access Alternative Information Resources (DAAIR), New York, NY
Marco Antonio se Castro Figueredo, Universidade de Sao Paulo, Sao Paulo, Brazil
Agni Castro Pita, Guayaquil, Ecuador
Jeannette Calvachi Noboa, Quito, Ecuador
David Cantero, MSF, Barcelona, Spain
Charles Clifton, Editor, Positively Aware, Test Positive Aware Network, Chicago, IL
Judith Cobeña Guardia, Associació Ciutadana AntiSida de Catalunya, Barcelona, Spain
Véronique Collard, TRT-5, Paris
Chris Collins, San Francisco, CA
Susan Cu-Uvin, MD, Immunology Center, The Miriam Hospital, Brown Univ., Providence RI
Lynda M. Dee, Esq., President, AIDS Action Baltimore, Baltimore, MD
Yvette Delph, MD, Antiviral Project Director, Treatment Action Group, Silver Spring, MD
Thomas J. Dionne, AIDSTALK, Washington, D.C.
Rubens Duda, President, Sao Paulo State AIDS/NGO Forum, Sao Paulo State, Brazil
Popho Earthwind, Information Center WOMYN FOR WOMYN
Marck A. Fedor, CEO, Click Technical Resources, Atlanta, GA
Timothy Flanigan, MD, Associate Professor of Medicine, Brown University, Providence, RI
Elena Font, Pueblos Hermanos. Madrid, España
Anna Forbes, Global Alliance for Microbicides
Joshua T. Formentera, President/Executive Director, Positive Action
Foundation Philippines, Manila
Kenneth Fornataro, Executive Director, AIDS Treatment Data Network, New York, NY
Carlos Gaon, Director, Fundación Vivir, Quito, Ecuador
Tony Garcia-Peleaz, PWA Coalition Colorado, Denver CO
John Gershman, Asia/Pacific Editor, Foreign Policy in Focus
Robin Gorna, Executive Director, Australian Federation of AIDS Organizations (AFAO), Sydney
Linda Grinberg, Foundation for AIDS Research (FAIR), Los Angeles, CA
Ian Grubb, Health Hounds Inc., Toronto, Canada
Mauro Guarneri, Italian Community Advisory Board, Rome, Italy
Jeff Gustavson, Survive AIDS, San Francisco, CA
Glen Hillson, British Columbia Persons With AIDS Society, Vancouver, British Columbia
Tim Horn, Physicians' Research Network, New York, NY
John Iversen, former co-chair, HIV Services Planning Council, Oakland, CA
John S. James, AIDS Treatment News, Philadelphia, PA
Richard Jefferys, AIDS Treatment Data Network, New York, NY
Samantha Johnston, SAATHI, New York, NY
Paul Akio Kawata, Executive Director, National Minority AIDS Council (NMAC), Washington, D.C.
Steve Kovacev, Provincetown Positive People with AIDS Coalition (PPPWAC), Provincetown, MA
Lark Lands, POZ Magazine, New York, NY
James Learned, Hepatitis C Action & Advocacy Coalition (HAAC), New York, NY
Roger Le Clerc, Director General, La COCQ-Sida, Montréal, Quebec, Canada
Luis Leiva Friedman, Asociación Costarricense de Personas que viven con VIH/SIDA / Red Latinamericana de PVVIH/SIDA para Costa Rica, San José, Costa Rica
Iris Long, Ph.D., AACTG CAB member at NYU Medical Center, New York, NY
Jordi D. Lopez, President, Stop Sida, Barcelona, Spain
Kathy Loucks, Inland Northwest AIDS Coalition, Spokane WA
James Love, Consumer Project on Technology, Washington, D.C.
Anuar Luna, Red Mexicana de Personas que Viven con VIH/SIDA, México City, México
Sharon Ann Lynch, HealthGAP Coalition, USA
Don MacIver, Chair, NYU Community Advisory Board, New York, NY
Carlos Maldonado, Director of Treatment & Prevention, Latino Commission on AIDS, New York, NY
Michael Marco, Oncology/Infections Director, Treatment Action Group
Valerie Papaya Mann, Executive Director, D.C. Care Consortium, Washington, D.C.
Derrick Mapp, Brooklyn, NY
Michelle Marchione, Canadian Treatment Advocates Council (CTAC)
Rev. Mother Mary Elizabeth, OSM, Sisters of St. Elizabeth of Hungary, CA
Lynne Mayer, Greensburg, PA
Craig McClure, Health Hounds Inc., Toronto, Canada
Rose McCullough, Executive Director, AIDS Vaccine Advocacy Coalition (AVAC), Washington, D.C.
Karen McKinnon, Director, Columbia University HIV Mental Health Training Project, New York, NY
Jorge Melguizo, Director de Cooperación, EDEX, Bilbao (Bizkaia), Spain
Shaun Mellors, AIDS Foundaiton of South Africa
Mary Anne Mercer, Co-chair, Northwest International Health Action Coalition, Seattle, WA
Michael Meulbroek, Projecte dels NOMS-SIDA, Catalonia, Spain
Mardie Millit, New York, NY
Orlando Montoya Herrera, Director Ejecutivo, Fundación Ecuatoriana EQUIDAD Quito, Ecuador
Bernardino Mosquera, Union Positiva, Miami, FL
Farai Mugweni, Southern Africa Network of AIDS Service Organizations (SANASO), Harare, Zimbabwe
Robert J. Munk, Ph.D., Arroyo Seco, NM
Vincent T. Neumann, Jr., Community Constituency Group, Adult AIDS Clinical Trials Group
Karen O'Shannacery, Executive Director, Lookout Emergency Aid Society, Vancouver, B.C., Canada
Donna Rae Palmer, Executive Director, Mobilization Against AIDS International, San Francisco
Rodrigo Pascal, President, VIVO POSITIVO, National PWA Coordinating Committee, Santiago, Chile
Janice Price, M.Ed., RN, HIV Research Coordinator, Seattle, WA
Regina Quattrochi, Bailey House, New York, NY
Margarita Quevedo, Directora Ejecutiva, Corporación Kimirina, Ecuador
Oswaldo A. Rada, Fundación Vivir Mejor, Cali, Colombia
Rita Raj
Claire Rappoport, Person with AIDS, Brisbane, CA
Maria Ines Re, Fundación para Estudio e Investigación de la Mujer, Buenos Aires, Argentina
Bill Reece
Yolanda Regalado, UNAPRO, Santa Cruz de Tenerife, Spain
Joseph W. Rios, Director, Association for the Treatment of AIDS in Guatemala
Wayne Roberts, National Coordinator, Australian Bisexual Network
Frank Rodenbourg, Secretary General, Actions Traitements, Paris, France
Carlos Alfonso Rodriguez.R, Fundación Isamar, Cuman=E1-Edo, Sucre, Venezuela
M. Jose Roman, SIDA-STUDI, Barcelona, Spain
Barry Rund, HCV Education/Case Management Program, Cambridge Health Alliance, Cambridge, MA
Luis G. Santiago, New York, NY
Jeffrey Schouten, MD, JD, Seattle Treatment Education Project, Seattle, WA
Matt Sharp, Person with AIDS, Chicago, IL
Dr. Stephen Shapiro, University of Warwick, United Kingdom
Maudelle Shirek, Vice Mayor, Berkeley, CA
Bill Snow, San Francisco, CA
Elsa Mónica Solis Zamudio, México
Clint Spencer, Community Advisory Board, U. of Hawaii AIDS Clinical Trials Unit, Honololu, HI
Peter Staley, AIDSMeds.com, New York, NY
Tracy Swan, Coordinator, HIV & HCV Outreach & Education Program, Cambridge Health Alliance (CHA), Cambridge, MA
Joan Tallada, Grupo de Trabajo sobre Tradatimento de VIH (GTT), Barcelona, Spain
Ezio Tavora dos Santos Filho, Grupo Pela VIDDA/Rio de Janeiro, Brazil
Dr. Ranga Uday Kumar, Retrovirology Laboratory, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore, India
Eulalia Vaquero Gómez, Confederación Española de Asociaciones de Padres de Alumnos (CEAPA), Madrid, España
Berndt Vielhaber, Berlin, Germany & Vels, Austria
Fehmida Visnegarwala, Assistant Professor of Medicine, Baylor College of Medicine, Houston, TX
Filippo von Schol=F6sser, NADIR, Rome, Italy; European AIDS Treatment Group (EATG)
Bill Wade, DO, MPH, Family Medicine & Counseling, St. Louis, MO
Dr. Gunto Aurel Weiler, Deutsche AIDS-Hilfe e.V., Berlin, Germany
Lee Wildes, Director, African AIDS Network
Phill Wilson, African American AIDS Policy Training Institute & AIDS Social Policy Archive, University of Southern California (USC), Los Angeles
Lee Zaslofsky, AIDS Committee of Toronto, Ontario, Canada
Dr. Pablo Enrique Zunino, Presidente, Fundación José de Arimatea, Guayaquil, Ecuador

cc: The Hon. Kofi Annan, U.N. Secretary General
    James Wolfensohn, World Bank
    Gro Harlem Brundtland, World Health Organization
    Peter Piot, M.D., UNAIDS
    The Hon. Thabo Mbeki, President, Republic of South Africa
    Dr. Manto Tshabalala-Msimang, Minister of Health, Republic of South Africa
    Zackie Achmat, Chairperson, Treatment Action Campaign, South Africa
    The Hon. Colin Powell, U.S. Secretary of State
    The Hon. Donald Evans, U.S. Secretary of Commerce
    Robert Zoellick, U.S. Trade Representative
    U.S. Congressional Black Caucus

This page provides ways of contacting your representatives. Action Alerts are posted on the National Association of People With AIDS site. Check out the AIDS Action Council for articles on current research and action alerts. Alerts also posted on ACT UP New York.

home

write to: webman@aidsinfonyc.org
copyright © 2001 aidsinfonyc.org